These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 30362847)
1. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726 [TBL] [Abstract][Full Text] [Related]
3. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956 [TBL] [Abstract][Full Text] [Related]
4. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea. Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839 [TBL] [Abstract][Full Text] [Related]
5. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695 [TBL] [Abstract][Full Text] [Related]
6. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030 [TBL] [Abstract][Full Text] [Related]
7. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351 [TBL] [Abstract][Full Text] [Related]
8. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075 [TBL] [Abstract][Full Text] [Related]
9. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676 [TBL] [Abstract][Full Text] [Related]
11. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. Lin KJ; Singer DE; Bykov K; Bessette LG; Mastrorilli JM; Cervone A; Kim DH JAMA Netw Open; 2023 Mar; 6(3):e234086. PubMed ID: 36976562 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001 [TBL] [Abstract][Full Text] [Related]
16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A; CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273 [TBL] [Abstract][Full Text] [Related]
18. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560 [TBL] [Abstract][Full Text] [Related]